Uli Hacksell, PhD

Chief Executive Officer (CEO)

San Diego, California, United States

Professional Overview
Uli Hacksell, PhD, is a seasoned pharmaceutical executive with over two decades of experience leading innovative biopharmaceutical companies. As the Chief Executive Officer of ACADIA Pharmaceuticals, he leverages his extensive expertise in drug development, regulatory affairs, and strategic business management to drive the company's mission of developing novel therapies for central nervous system (CNS) disorders.

Experience Summary

Current Role
As the CEO of ACADIA Pharmaceuticals since 2000, Dr. Hacksell has been instrumental in the company's growth and success. Under his leadership, ACADIA has brought to market NUPLAZID® (pimavanserin), the first and only FDA-approved treatment for Parkinson's disease psychosis. Dr. Hacksell has played a pivotal role in navigating the complex regulatory landscape, securing key approvals, and advancing ACADIA's robust pipeline of innovative CNS drug candidates.

Career Progression
Prior to joining ACADIA, Dr. Hacksell held several senior leadership positions in the pharmaceutical industry, including serving as the Chief Executive Officer of ASTRA PAIN CONTROL AB and the Executive Vice President of Drug Discovery at ASTRA AB. His extensive experience in drug discovery, development, and commercialization has been instrumental in driving ACADIA's growth and positioning the company as a leader in the CNS therapeutics space.

Academic Background
Dr. Hacksell holds a Ph.D. in Organic Chemistry from the Royal Institute of Technology in Stockholm, Sweden. He has authored numerous scientific publications and holds several patents, demonstrating his deep understanding of the pharmaceutical industry and his commitment to innovation.

Areas of Expertise

• Drug discovery and development

• Regulatory affairs and strategic planning

• CNS therapeutics, with a focus on Parkinson's disease and other neurological disorders

• Pharmaceutical business strategy and operations

• Effective leadership and team management

Professional Impact
Under Dr. Hacksell's guidance, ACADIA has become a recognized leader in the development of innovative CNS therapies. The successful launch and commercialization of NUPLAZID® have had a significant impact on the treatment of Parkinson's disease psychosis, improving the quality of life for patients and their caregivers. Additionally, Dr. Hacksell's leadership has been instrumental in advancing ACADIA's robust pipeline of drug candidates, positioning the company for continued growth and success.

Conclusion
With his extensive experience in the pharmaceutical industry, strong scientific background, and proven track record of success, Uli Hacksell, PhD, is a visionary leader who has consistently driven ACADIA Pharmaceuticals' growth and innovation. His commitment to developing transformative CNS therapies has positioned the company as a leader in the field and made a meaningful impact on the lives of patients and their families.